Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties

References

• Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2014;130(4):333–346. doi:10.1161/CIRCULATIONAHA.113.00689825047584
   PubMed Web of Science ®Google Scholar
• Renkin EM. Cellular aspects of transvascular exchange: a 40-year perspective. Microcirculation. 1994;1(3):157–167.8790586
   PubMedGoogle Scholar
• Arnould T, Janssens D, Michiels C, Remacle J. Effect of aescine on hypoxia-induced activation of human endothelial cells. Eur J Pharmacol. 1996;315(2):227–233. doi:10.1016/s0014-2999(96)00645-08960888
   PubMed Web of Science ®Google Scholar
• Montopoli M, Froldi G, Comelli MC, Prosdocimi M, Caparrotta L. Aescin protection of human vascular endothelial cells exposed to cobalt chloride mimicked hypoxia and inflammatory stimuli. Planta Med. 2007;73(3):285–288. doi:10.1055/s-2007-96711817310430
   PubMed Web of Science ®Google Scholar
• Arcelus A, Caprini JA. Non-operative treatment of chronic venous insufficiency. J Vasc Tech. 2002;26(3):231–238.
   Google Scholar
• Bombardelli E, Morazzoni P, Griffini A. Aesculus hippocastanum L. Fitoterapia. 1996;67(6):483–511.
   Google Scholar
• Chauhan R, Ruby K, Dwivedi J. Golden herbs used in piles treatment: a concise report. Int J Drug Dev Res. 2012;4(4):50–68.
   Google Scholar
• European Medicines Agency. Assessment report on Aesculus Hipoocastanum L., semen; 2009 Available from: http://www.ema.europa.eu/documents/herbal-report/assessment-report-aesculus-hippocastanum-l-semen_en.pdf. Accessed 1030, 2018.
   Google Scholar
• Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44(3):183–193. doi:10.1006/phrs.2001.084711529685
   PubMed Web of Science ®Google Scholar
• Diehm C, Vollbrecht D, Amendt K, Comberg HU. Medical edema protection–clinical benefit in patients with chronic deep vein incompetence. A placebo controlled double blind study. Vasa. 1992;21(2):188–192.1621440
   PubMed Web of Science ®Google Scholar
• Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet. 1996;347(8997):292–294. doi:10.1016/s0140-6736(96)90467-58569363
   PubMed Web of Science ®Google Scholar
• Lorenz D, Marek ML. [The active therapeutic principle of horse chestnut (Aesculus hippocastanum). Part 1. Classification of the active substance]. Arzneimittelforschung. 1960;10:263–272. [Article in German].14418281
   PubMed Web of Science ®Google Scholar
• Pietta P, Mauri PJ. High-performance liquid chromatographic analysis of β-escin. J Chromatogr. 1989;478:259–263. doi:10.1016/S0021-9673(01)84394-6
   Web of Science ®Google Scholar
• Henschler D, Hempel K, Schultze B, Maurer W. [The pharmakokinetics of escin]. Arzneimittelforschung. 1971;21(11):1682–1692. [Article in German].5172078
   PubMed Web of Science ®Google Scholar
• Meyer-Bertenrath J, Kaffarnik H. [Enteral resorption of aescin]. Arzneimittelforschung. 1970;20(1):147–148. [Article in German].5467438
   PubMed Web of Science ®Google Scholar
• Madaus R, Erhring H, Winkler W. Reabsorbable aescin composition and method of making. US Patent Application: US3238104A. 1963 Available from: http://patents.google.com/patent/US3238104A/en. Accessed 17, 2019.
   Google Scholar
• Michiels C, Arnould T, Knott I, Dieu M, Remacle J. Stimulation of prostaglandin synthesis by human endothelial cells exposed to hypoxia. Am J Physiol. 1993;264(4 Pt 1):C866–c874. doi:10.1152/ajpcell.1993.264.4.C8668476019
   PubMed Web of Science ®Google Scholar
• Arnould T, Michiels C, Remacle J. Increased PMN adherence on endothelial cells after hypoxia: involvement of PAF, CD18/CD11b, and ICAM-1. Am J Physiol. 1993;264(5 Pt 1):C1102–C1110. doi:10.1152/ajpcell.1993.264.5.C11028098907
   PubMed Web of Science ®Google Scholar
• Dudek-Makuch M, Studzinska-Sroka E. Horse chestnut – efficacy and safety in chronic venous insufficiency: an overview. Braz J Pharmacogn. 2015;25(5):533–541. doi:10.1016/j.bjp.2015.05.009
   Web of Science ®Google Scholar
• Girerd RJ, Di Pasquale G, Steinetz BG, Beach VL, Pearl W. The anti-edema properties of aescin. Arch Int Pharmacodyn Ther. 1961;133:127–137.13898912
   PubMedGoogle Scholar
• Hampel H, Hofrichter G, Liehn HD, Schlemmer W. [Pharmacology of aescin-isomers with special reference to alpha-aescin]. Arzneimittelforschung. 1970;20(2):209–215. [Article in German].5467465
   PubMed Web of Science ®Google Scholar
• Rothkopf M, Vogel G. [New findings on the efficacy and mode of action of the horse chestnut saponin escin]. Arzneimittelforschung. 1976;26(2):225–235. [Article in German].947203
   PubMed Web of Science ®Google Scholar
• Rothkopf M, Vogel G, Lang W, Leng E. Animal experiments on the question of the renal toleration of the horse chestnut saponin aescin. Arzneimittelforschung. 1977;27(3):598–605. [Article in German].301389
   PubMed Web of Science ®Google Scholar
• Facino RM, Carini M, Stefani R, Aldini G, Saibene L. Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency. Arch Pharm (Weinheim). 1995;328(10):720–724.8554461
   PubMed Web of Science ®Google Scholar
• Zhao SQ, Xu SQ, Cheng J, et al. Anti-inflammatory effect of external use of escin on cutaneous inflammation: possible involvement of glucocorticoids receptor. Chin J Nat Med. 2018;16(2):105–112. doi:10.1016/S1875-5364(18)30036-029455725
   PubMed Web of Science ®Google Scholar
• Xin W, Zhang L, Sun F, et al. Escin exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vivo and in vitro. Phytomedicine. 2011;18(4):272–277. doi:10.1016/j.phymed.2010.08.01320850956
   PubMed Web of Science ®Google Scholar
• Wang T, Zhao S, Wang Y, et al. Protective effects of escin against indomethacin-induced gastric ulcer in mice. Toxicol. 2014;24(8):560–566.
   Web of Science ®Google Scholar
• Annoni F, Mauri A, Marincola F, Resele LF. [Venotonic activity of escin on the human saphenous vein]. Arzneimittelforschung. 1979;29(4):672–675. [Article in German].582766
   PubMed Web of Science ®Google Scholar
• Longiave D, Omini C, Nicosia S, Berti F. The mode of action of aescin on isolated veins: relationship with PGF2 alpha. Pharmacol Res Commun. 1978;10(2):145–152.652841
   PubMedGoogle Scholar
• Brunner F, Hoffmann C, Schuller-Petrovic S. Responsiveness of human varicose saphenous veins to vasoactive agents. Br J Clin Pharmacol. 2001;51(3):219–224. doi:10.1046/j.1365-2125.2001.00334.x11298067
   PubMed Web of Science ®Google Scholar
• Bougelet C, Roland IH, Ninane N, Arnould T, Remacle J, Michiels C. Effect of aescine on hypoxia-induced neutrophil adherence to umbilical vein endothelium. Eur J Pharmacol. 1998;345(1):89–95. doi:10.1016/s0014-2999(97)01616-69593599
   PubMed Web of Science ®Google Scholar
• Carrasco OF, Vidrio H. Endothelium protectant and contractile effects of the antivaricose principle escin in rat aorta. Vascul Pharmacol. 2007;47(1):68–73. doi:10.1016/j.vph.2007.04.00317512261
   PubMed Web of Science ®Google Scholar
• Domanski D, Zegrocka-Stendel O, Perzanowska A, et al. Molecular mechanism for cellular response to beta-escin and its therapeutic implications. PLoS One. 2016;11(10):e0164365. doi:10.1371/journal.pone.016436527727329
   PubMed Web of Science ®Google Scholar
• Wang X-H, Xu B, Liu J-T, Cui J-R. Effect of beta-escin sodium on endothelial cells proliferation, migration and apoptosis. Vascul Pharmacol. 2008;49(4–6):158–165. doi:10.1016/j.vph.2008.07.00518718875
   PubMed Web of Science ®Google Scholar
• Lang W, Mennicke WH. [Pharmacokinetic studies on triatiated aescin in the mouse and rat]. Arzneimittelforschung. 1972;22(11):1928–1932.4679067
   PubMed Web of Science ®Google Scholar
• Wu X-J, Zhang M-L, Cui X-Y, et al. Comparative pharmacokinetics and bioavailability of escin Ia and isoescin Ia after administration of escin and of pure escin Ia and isoescin Ia in rat. J Ethnopharmacol. 2012;139(1):201–206. doi:10.1016/j.jep.2011.11.00322094055
   PubMed Web of Science ®Google Scholar
• Lang W. [Percutaneous absorption of 3H-aescin in mice and rats]. Arzneimittelforschung. 1974;24(1):71–76. [Article in German].4406113
   PubMed Web of Science ®Google Scholar
• Lang W. Studies on the percutaneous absorption of 3H-aescin in pigs. Res Exp Med (Berl). 1977;169(3):175–187.841186
   PubMedGoogle Scholar
• Stenton SB, Bungard TJ, Ackman ML. Interactions between warfarin and herbal products, minerals, and vitamins: a pharmacist’s guide. Can J Hosp Pharm. 2001;54:186–192.
   Google Scholar
• Anonymous. Aesculus hippocastanum (horse chestnut). Alt Med Rev. 2009;14(3):278–283.
   PubMedGoogle Scholar
• Hernandez Carbajal B, Bravo Bernabe PA, Cruz Cruz M, Fernandez Garcia A, Zarraga Cobrales J. Clinical trials of treatment with amorphous aescin (reparil sugar coated tablets) in 100 patients with post-plaster and post-traumatic edema, 20 of such patients being given placebo. Madaus report; 1971.
   Google Scholar
• Tsuyama N. Clinical evaluation of the anti-swelling drug A-4700 (reparil tablet) in the orthopaedic field. Clin Eval. 1977;5(3):535–575.
   Google Scholar
• Hoffmann J, Day U-H, Schneider B, Böhnert K-J. Clinical trial of reparil coated tablets on patients with chronic venous insufficiency. Med Welt. 1988;39:945–950.
   Google Scholar
• Vasquez Camacho L. A double-blind investigation of certain disorders of the veins of the pelvis and legs. MMW Munch Med Wochenschr. 1975;117(2):108–111.
   Google Scholar
• Bahr R, Krosshaug T. Understanding injury mechanisms: a key component of preventing injuries in sport. Br J Sports Med. 2005;39(6):324–329. doi:10.1136/bjsm.2005.01834115911600
   PubMed Web of Science ®Google Scholar
• Serra MB, Barroso WA, da Silva NN, et al. From inflammation to current and alternative therapies involved in wound healing. Int J Inflam. 2017;2017:3406215. doi:10.1155/2017/340621528811953
   PubMed Web of Science ®Google Scholar
• Rothhaar J, Thiel W. [Percutaneous gel therapy of blunt athletic injuries]. Med Welt. 1982;33(27):1006–1010. [Article in German].7144496
   PubMed Web of Science ®Google Scholar
• Bonnekoh A, Rost R, Völker K, Giannetti BM, Bulitta M, Ley F. Double-blind controlled clinical trial comparing an aescin combination gel with diclofenac diethylamine salt gel for efficacy and tolerability in volunteers with injection-induced haematoma. Dtsch Z Sportmed. 1992;43(3):1–10.
   Google Scholar
• Pabst H, Segesser B, Bulitta M, Wetzel D, Bertram S. Efficacy and tolerability of escin/diethylamine salicylate combination gels in patients with blunt injuries of the extremities. Int J Sports Med. 2001;22(6):430–436. doi:10.1055/s-2001-1625111531036
   PubMed Web of Science ®Google Scholar
• Wetzel D, Menke W, Dieter R, Smasal V, Giannetti B, Bulitta M. Escin/diethylammonium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study. Br J Sports Med. 2002;36(3):183–188. doi:10.1136/bjsm.36.3.18312055112
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Day U-H, Schneider B, Böhnert K-J. [Percutaneous treatment of chronic venous insufficiency with an aescin-containing gel. A randomized placebo-controlled double-blind trial]. Med Welt. 1988;39:951–955. [Article in German].
   Web of Science ®Google Scholar
• Siebert U, Brach M, Sroczynski G, Berla K. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. Int Angiol. 2002;21(4):305–315.12518108
   PubMed Web of Science ®Google Scholar